Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not so NICE for Avastin

Executive Summary

The U.K.'s National Institute for Health and Clinical Excellence terminates its review of Roche/Genentech's Avastin (bevacizumab) for first-line metastatic breast cancer because the sponsor failed to submit sufficient evidence, the regulatory body announces June 25. Avastin received approval for a breast cancer indication in the U.S. in February. NICE also stopped its review of Avastin for the first-line treatment of metastatic or recurrent non-small cell lung cancer, another indication approved in the U.S. Review of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) for second-line treatment of colorectal cancer was similarly terminated due to the failure to submit sufficient evidence
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel